A share price of Actinium Pharmaceuticals Inc [ATNM] is currently trading at $1.52, up 6.29%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ATNM shares have gain 16.92% over the last week, with a monthly amount drifted -5.59%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Actinium Pharmaceuticals Inc [AMEX: ATNM] stock has seen the most recent analyst activity on August 07, 2024, when B. Riley Securities downgraded its rating to a Neutral and also revised its price target to $2 from $16. Previously, Stephens started tracking the stock with Overweight rating on May 14, 2024, and set its price target to $25. On September 06, 2023, HSBC Securities initiated with a Buy rating and assigned a price target of $11.60 on the stock. William Blair downgraded its rating to a Mkt Perform. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $20 as its price target on September 08, 2022. B. Riley Securities started tracking with a Buy rating for this stock on August 25, 2022, and assigned it a price target of $16. In a note dated November 05, 2020, Alliance Global Partners initiated an Buy rating and provided a target price of $25 on this stock.
Actinium Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.03 and $10.24. Currently, Wall Street analysts expect the stock to reach $11.07 within the next 12 months. Actinium Pharmaceuticals Inc [AMEX: ATNM] shares were valued at $1.52 at the most recent close of the market. An investor can expect a potential return of 628.29% based on the average ATNM price forecast.
Analyzing the ATNM fundamentals
Trailing Twelve Months sales for Actinium Pharmaceuticals Inc [AMEX:ATNM] were 0.00M which represents -100.00% decline. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.96 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4033 points at the first support level, and at 1.2867 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5783, and for the 2nd resistance point, it is at 1.6367.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Actinium Pharmaceuticals Inc [AMEX:ATNM] is 9.14. Further, the Quick Ratio stands at 9.14, while the Cash Ratio is 8.95.
